Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474

  • JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ:KYMR) with a Neutral rating and a $44 price target
  • Analyst Eric Joseph says that the Company is "relatively insulated from downside pressure versus the benchmark from a healthy balance sheet." 
  • At the end of 2021, Kymera held approximately $567.6 million in cash, cash equivalents, and investments.
  • Joseph also adds that Kymera has limited upside potential from anticipated biomarker updates from KT-474 and the earlier stage pipeline over the mid-term.
  • Kymera Therapeutics completed dose escalation in the KT-474 single-ascending dose and multiple-ascending dose portions of the Phase 1 trial.
  • In December, the disclosed additional KT-474 data, with near-complete IRAK4 degradation in peripheral blood mononuclear cells (PBMC) and skin, and favorable safety profile. 
  • Hidradenitis suppurativa and atopic dermatitis patient cohort data expected in 2H22.
  • Related: Kymera Discloses New Development Cancer Program.
  • Kymera is collaborating with Sanofi SA (NASDAQ:SNY) to develop degrader candidates targeting IRAK4, including KT-474, outside of the oncology and immune-oncology fields.
  • Price Action: KYMR shares are down 3.21% at $38.84 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.